Online CME

How to Obtain AMA PRA Category 1 Credit

  1. Complete the Activity.
  2. Complete the CME posttest (each question must be answered correctly).
  3. Log into your myCME account.
  4. Complete the credit and evaluation form.
  5. Print your personalized CME certificate.
  6. Credit can only be claimed once for this activity.

Cleveland Clinic Tumor Boards

Current Issues in the Management
of Non-Small Cell Lung Cancer:
Treatment of ALK-Positive Disease and
Use of Stereotactic Body Radiotherapy in Oligometastatic Lung Cancer

Print this Content

Release Date: March 31, 2016
Expiration Date: March 31, 2017

Estimated Time of Completion: 1 hour

Description

This tumor board webcast focuses on current progress in the treatment of patients with non-small cell lung cancer. The multidisciplinary faculty present various aspects of the case, including management of crizotinib resistance in patients with ALK-positive disease, the role of ALK inhibitors for treatment, assessment of the proper radiation dose and potential toxicities associated with SBRT, and the methodology and current guidelines for ALK testing. Treatment of ALK-positive disease and use of stereotactic body radiotherapy in oligometastatic lung cancer are also presented.

Learning Objectives

  1. Appraise recent data on the management of crizotinib resistance in patients with ALK-positive disease.
  2. Assess the role of ALK inhibitors for treatment of patients with ALK-positive NSCLC.
  3. Discuss assessment of the proper radiation dose and potential toxicities associated with SBRT in these patients.
  4. Explain the methodology and current guidelines for ALK testing in patients with NSCLC.
  5. Restate indications for use of SBRT in patients with early-stage unresectable NSCLC and oligometastatic disease, and summarize results of key clinical trials.

Target Audience

This activity is designed for health care practitioners including medical and surgical oncologists, pathologists, pulmonologists, radiologists, surgeons, and other health care professionals who manage patients with lung cancer.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Director and Faculty

Activity Directors
Jame Abraham, MD

Jame Abraham, MD
Director, Breast Oncology Program at Taussig Cancer Institute
Co-Director of the Cleveland Clinic Multidisciplinary Breast Cancer Program
Cleveland Clinic
Cleveland, OH

Nathan Pennell, MD, PhD
Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Faculty

Carol Farver, MD
Lung Pathology
Department of Anatomic Pathology
Cleveland Clinic
Cleveland, OH

Roger Klein, MD, JD
Molecular Pathology
Clinical Pathology
Cleveland Clinic
Cleveland, OH

Kevin Stephans, MD
Radiation Oncology
Cleveland Clinic
Cleveland, OH

Vamsidhar Velcheti, MD
Assistant Professor
Cleveland Clinic Lerner College of Medicine at Case Western University
Medical Oncology
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentations, could be perceived as a potential conflict of interest:

Nathan Pennell, MD
  Astra Zeneca; Boehringer Ingelheim Consulting
Vamsidhar Velcheti, MD
  Novartis Oncology; Foundation Medicine Teaching and Speaking

The following faculty have indicated they have no relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:

Jame Abraham, MD
Carol Farver, MD
Roger Klein, MD
Kevin Stephans, MD

All other planners, CME staff, and content reviewers, have no relevant financial relationships to disclose.

The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for support of this activity from:

Genentech

This CME activity was produced by Cleveland Clinic Foundation Center for Continuing Education, Taussig Cancer Institute and Harborside Press.